SCYNEXIS, Inc.

SCYXNASDAQ • USD
2.91 USD
↘ 0.30 (9.35%)AT CLOSE (03:59 PM EST)
2.89
↘ 0.03 (0.86%)
POST MARKET (AS OF 07:30 PM EST)
Post Market
AS OF 07:30 PM EST
2.89
↘ 0.03 (0.86%)
🔴Market: CLOSED

SCYX is currently priced at $2.94. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest SCYX is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Nov 16, 2026.

Open?$3.23
High?$3.23
Low?$2.84
Prev. Close?$3.21
Volume?88.1K
Avg. Volume?92.8K
VWAP?$2.98
Rel. Volume?0.95x
Bid / Ask
Bid?$2.88 × 200
Ask?$2.95 × 100
Spread?$0.07
Midpoint?$2.92
Valuation & Ratios
Market Cap?31.9M
Shares Out?10.0M
Float?9.0M
Float %?90.3%
P/E Ratio?N/A
P/B Ratio?0.54
EPS?-$1.01
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Employees
29
Market Cap
31.9M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2014-05-02
Address
1 EVERTRUST PLAZA
JERSEY CITY, NJ 07302-6548
Phone: 201-884-5485
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
44
Piotroski F-Score?0/9Weak
Altman Z-Score?-6.36Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?5.01%Elevated
Short Interest?450.2K
Days to Cover?5.6
Free Float9.0M
Avg Daily Volume81.1K
Settlement Date2026-10-30
Financial Health
Current Ratio?7.57Strong
Quick Ratio?7.57Strong
Cash Ratio?1.24Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.54CHEAP▾
P/S?
Peers
100
S&P
75
1.69CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.0CHEAP▾
EV/Sales?
Peers
100
S&P
88
1.26CHEAP▾
Returns & Efficiency
ROE?
S&P
8
-17.1%WEAK▾
ROA?
S&P
3
-14.9%WEAK▾
Cash Flow & Enterprise
FCF?$-12051000
Enterprise Value?$23.7M
Fundamentals ratios updated end of day